Latest News

Stay up to date with the latest stock market news from around the world. From breaking news written by our finance analysts to event-driven market news on a global scale.

ENXTAM:PRX
ENXTAM:PRXMultiline Retail

Does Prosus’ Special Investor Call Signal a Shift in Its Capital Allocation Playbook (ENXTAM:PRX)?

Prosus N.V. recently held a Special Call, drawing attention as the company flagged that it would share important corporate updates with investors. The Special Call stands out because such events can signal meaningful shifts in a company’s priorities, capital allocation approach, or portfolio decisions. We will now examine how Prosus’s Special Call, and the expectations it creates around potential corporate updates, shapes its investment narrative. Trump's oil boom is here - pipelines are...
TSE:4204
TSE:4204Industrials

Sekisui Chemical (TSE:4204) Margin Compression Reinforces Bearish Narratives After Q3 2026 Results

Sekisui Chemical (TSE:4204) has released its Q3 2026 numbers, reporting total revenue of ¥330.1b and basic EPS of ¥39.16. This gives investors another data point on how the year is shaping up. Over the past six reporting periods, the company’s quarterly revenue has moved between ¥324.7b and ¥342.4b, while basic EPS has ranged from ¥31.60 to ¥61.12. This quarter sits somewhere in the middle, keeping margins and earnings quality in focus. See our full analysis for Sekisui Chemical. With the...
HLSE:SAMPO
HLSE:SAMPOInsurance

A Look At Sampo Oyj’s (HLSE:SAMPO) Valuation After Recent Flat Share Price And Mixed Return Performance

Setting the scene for Sampo Oyj (HLSE:SAMPO) Sampo Oyj (HLSE:SAMPO) has attracted attention after a flat one day move at €9.40, set against mixed recent returns and steady reported revenue of €10.362b and net income of €1.641b. See our latest analysis for Sampo Oyj. While the 7 day share price return of 1.62% offers a small rebound, the 30 day and year to date share price declines of 9.00% and 8.20% suggest momentum has cooled. At the same time, the 1 year total shareholder return of 22.78%...
TSE:7148
TSE:7148Diversified Financial

Financial Partners GroupLtd (TSE:7148) Margin Compression In Q1 2026 Tests Bullish Growth Narratives

Financial Partners GroupLtd (TSE:7148) Q1 2026 results in focus Financial Partners GroupLtd (TSE:7148) has kicked off Q1 2026 with revenue of ¥14,997 million and basic EPS of ¥50.49, alongside net income of ¥4,228 million, setting a clear marker for how the new fiscal year is beginning. The company has seen quarterly revenue move from ¥27,963 million and EPS of ¥64.76 in Q1 2025 to ¥39,066 million and EPS of ¥52.59 in Q4 2025, with trailing twelve month revenue at ¥116,798 million and EPS at...
NasdaqCM:PDEX
NasdaqCM:PDEXMedical Equipment

Pro Dex (PDEX) One Off Gain Clouds 68% Trailing Earnings Growth Narrative

Pro-Dex (PDEX) has released its Q2 2026 numbers, reporting revenue of US$18.7 million and Basic EPS of US$0.67. The company’s quarterly revenue moved from US$16.8 million and EPS of US$0.63 in Q2 2025 to US$18.7 million and EPS of US$0.67 in Q2 2026, while trailing twelve month revenue reached US$72.1 million alongside Basic EPS of US$3.48. Together with a trailing year net margin of 15.7%, these figures highlight how much of the current margin profile comes from the core business rather than...
TSX:ATZ
TSX:ATZSpecialty Retail

A Look At Aritzia’s Valuation After Brian Hill’s CA$200 Million Secondary Share Sale

Why Brian Hill’s share sale matters for Aritzia Aritzia (TSX:ATZ) is back in focus after founder and executive chair Brian Hill completed a secondary sale of more than 1.5 million subordinate voting shares. This roughly CA$200 million liquidity event shifts insider ownership. See our latest analysis for Aritzia. The secondary offering comes after a volatile period for the stock, with a 7-day share price return showing a 10.24% decline and a 30-day share price return showing an 8.54% decline...
NasdaqGM:NEWT
NasdaqGM:NEWTDiversified Financial

NewtekOne (NEWT) Net Margin Improvement Challenges Bearish Earnings Narratives

NewtekOne FY 2025 earnings snapshot NewtekOne (NEWT) has put up another solid set of numbers for FY 2025 so far, with Q3 revenue at US$99.5 million and basic EPS of US$0.68 alongside net income of US$17.4 million. The company has seen quarterly revenue move from US$81.4 million and EPS of US$0.43 in Q2 2024 to US$92.8 million and US$0.53 in Q2 2025, and more recently US$99.5 million and US$0.68 in Q3 2025. This feeds into trailing twelve month EPS of US$2.27 on revenue of US$380.4 million...
NasdaqGS:TENB
NasdaqGS:TENBSoftware

Assessing Tenable Holdings (TENB) Valuation After Launch Of Tenable One AI Exposure Platform

AI Exposure launch puts Tenable Holdings (TENB) in focus Tenable Holdings (TENB) has rolled out Tenable One AI Exposure, a new capability within its exposure management platform that targets AI related risk across SaaS, cloud services, APIs and on premises environments. The launch centers on unified visibility into sanctioned and shadow AI, contextual insight into how AI ties into infrastructure and identities, and tools for reducing AI related exposure and supporting governance and...
TSE:5401
TSE:5401Metals and Mining

Nippon Steel BlueScope Talks Raise Questions On Growth Versus Balance Sheet

Nippon Steel (TSE:5401) has been in discussions with BlueScope after BlueScope rejected a separate takeover offer from another party. The talks reportedly cover options such as a full acquisition of BlueScope or the purchase of a minority stake. If a deal progresses, it would mark a significant cross border move in the global steel sector. Nippon Steel is one of Japan's largest steel producers, with operations that span flat steel products, long products and related processing. Any...
NasdaqGS:NBIS
NasdaqGS:NBISSoftware

Nebius Wins Israel AI Supercomputer Role And Expands Infrastructure Story

Nebius Group (NasdaqGS:NBIS) has been selected by the Israel Innovation Authority to operate and develop Israel’s national AI supercomputer infrastructure. The decision follows a competitive process and places Nebius at the core of Israel’s AI compute capabilities. The mandate covers both the buildout and ongoing operation of high performance infrastructure for AI workloads. Nebius Group focuses on cloud and AI infrastructure, an area that has attracted growing attention as more workloads...
NasdaqGS:CNOB
NasdaqGS:CNOBBanks

ConnectOne Bancorp Marks Largest Deal And Push Into AI Efficiency

ConnectOne Bancorp (NasdaqGS:CNOB) completed the largest transaction in its history. The bank executed a full systems conversion shortly after the deal closed. The company outlined plans to consolidate branches and expand use of technology and AI. ConnectOne Bancorp, a regional banking company focused on commercial and consumer clients, is entering a period of operational change that goes beyond its usual financial updates. Completing its biggest deal to date alongside a full systems...
NYSE:FICO
NYSE:FICOSoftware

Is It Time To Reassess Fair Isaac (FICO) After The Recent Share Price Slide

If you are wondering whether Fair Isaac's premium share price still lines up with its underlying value, or if expectations have run ahead of the fundamentals, this article walks through the numbers in a clear, practical way. The stock last closed at US$1,463.17, with returns of a 5.3% decline over 7 days, a 13.5% decline over 30 days, an 11.0% decline year to date and a 21.9% decline over 1 year, set against very large gains over 3 and 5 years of 114.8% and 206.2% respectively. Recent...
NasdaqGS:BUSE
NasdaqGS:BUSEBanks

How Investors Are Reacting To First Busey (BUSE) Earnings Beat, Leadership Change And Buyback Completion

In late January 2026, First Busey Corporation reported fourth-quarter 2025 results showing higher net interest income of US$157,560,000 and net income of US$60,750,000 year on year, while confirming the separation of longtime executive Michael J. Maddox and related leadership changes at Busey Bank. The quarter also featured robust revenue that surpassed analyst expectations, record wealth management fee income driven by higher assets under care, and completion of a long-running share...
ASX:RMS
ASX:RMSMetals and Mining

Assessing Ramelius Resources (ASX:RMS) Valuation Ahead Of The Q2 2026 Earnings Call

Why the upcoming Q2 call matters for Ramelius Resources Interest in Ramelius Resources (ASX:RMS) is picking up as investors look ahead to the Q2 2026 earnings call on 29 January, which is expected to update the market on financial and operational performance. See our latest analysis for Ramelius Resources. At a share price of A$4.72, Ramelius has seen a 13.46% 30 day share price return and 42.17% 90 day share price return. Its 1 year total shareholder return of 96.45% and very large 3 year...
NYSE:ROK
NYSE:ROKElectrical

Is Rockwell Automation (ROK) Pricing Reflect Strong Share Gains Or Stretching Valuation Limits

If you are wondering whether Rockwell Automation's current share price lines up with its underlying value, you are not alone. This article focuses squarely on what the numbers can and cannot tell you about that question. The stock most recently closed at US$421.65, with stated returns of 0.9% over 7 days, 8.4% over 30 days, 5.8% year to date, 53.9% over 1 year, 53.2% over 3 years and 89.1% over 5 years. Recent coverage has highlighted Rockwell Automation as a key name in industrial...
NYSE:BHC
NYSE:BHCPharmaceuticals

Phase 3 RED-C Miss for Hepatic Encephalopathy Prevention Might Change The Case For Investing In Bausch Health Companies (BHC)

In January 2026, Bausch Health Companies Inc. reported that its global Phase 3 RED-C program testing amorphous-rifaximin solid soluble dispersion in adults with liver cirrhosis for primary prevention of hepatic encephalopathy did not meet its primary endpoint, despite a favorable safety and tolerability profile. This outcome highlights both the clinical challenges in preventing hepatic encephalopathy and the implications for Bausch Health’s efforts to expand its hepatology pipeline. We...
SEHK:1681
SEHK:1681Pharmaceuticals

Consun Pharmaceutical Group (SEHK:1681) Valuation Check After Expanded HK$300 Million Share Buyback Plan

Consun Pharmaceutical Group expands buyback plan Consun Pharmaceutical Group (SEHK:1681) has expanded its existing share repurchase plan, adding HK$100 million to the programme to allow for up to HK$300 million in potential buybacks funded from existing cash resources. See our latest analysis for Consun Pharmaceutical Group. The increased buyback plan comes after a strong run in the shares, with a 15.54% 1 month share price return and a 20.23% 3 month share price return helping support a very...